Home › Breast Cancer › NCT05396612

Role of the Immune Environment in Response to Therapy in Breast Cancer

Who can join

Ages 18 and older · Women

Inclusion criteria:

Women 18 years of age or older with non-metastatic breast cancer undergoing surgical resection in the University of Pennsylvania Health System.

Exclusion criteria:

Males Children Pregnant individuals

About the study

This is an observational case-control study of tissues collected from women with ER+HER2- breast cancers. The immune environments of these cancers will be compared to triple negative and HER2+ breast cancers. No randomization or changes to standard of care treatment will occur as part of the study.

What is being tested

• Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver. (other)

Sponsor: Abramson Cancer Center at Penn Medicine · Participants: 300 · Started: Oct 3, 2022

Contact the study team

• Julia T. Lewandowski · Phone: 215-662-2861
• Jennifer Zhang, MD · Phone: 215-615-6810

Official record on ClinicalTrials.gov — NCT05396612

Locations in the U.S.

Conditions

• Breast Cancer
• Triple-Negative Breast Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.